24 January 2024
Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies. The guideline was published in the non-profit open access journal PLOS Medicine.
The publication of clinical study results is key to communicating how well medicines can treat diseases. It is vital that these results are made available as quickly as possible, so it’s important to know what influences the ‘time to publication’ (the time from the end of the study to publication of the results in a…
Effective innovation happens when we ask big questions. It’s part of what makes Oxford PharmaGenesis an award-winning, independent, global HealthScience communications consultancy. We innovate for clients through our transformative services. We offer expertise in publications, strategic medical communications, informatics and data science, patient engagement, value demonstration, Open Pharma, social media, and more.
ORCID iDs are digital identity tags for authors of research papers. Authors who sign up to ORCID are given a unique number, which is linked to an online profile where they can add information about where they work and their education, awards and published works. Authors can add their ORCID iD to any research papers…
We were honoured on Friday as King Charles III’s representative in Oxfordshire, Lord-Lieutenant Marjorie Glasgow BEM, presented our HealthScience Communications Consultancy with a 2023 King’s Award at our head office just outside Oxford, UK.
Oxford PharmaGenesis is proud to have been a finalist for the prestigious 2023 Communiqué Leadership Award for Action on Workforce Diversity and Inclusion. The awards ceremony took place on Thursday 6 July at the Dorchester Hotel, London, UK.
We have scored a hat-trick, with media brand Medical Marketing and Media (MM+M) listing Oxford PharmaGenesis in its Agency 100 report for a third consecutive year.
